Correspondence 0001171843-23-006726 from AlphaTON Capital Corp (ATON)

AlphaTON Capital Corp
Date: Nov. 3, 2023 · CIK: 0001095435 · Accession: 0001171843-23-006726

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275229

Date

November 3, 2023

Author

Not clearly detected

Form

CORRESP

Company

AlphaTON Capital Corp

Letter

PORTAGE BIOTECH INC.

Clarence Thomas Building, P.O. Box 4649

Road Town, Tortola

British Virgin Islands, VG1110

November 3, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Dillon Hagius

Re: Portage Biotech Inc.

Registration Statement on Form F-1

Filed October 31, 2023

File No. 333-275229

Request for Acceleration of Effective Date

Mr. Hagius:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Portage Biotech Inc. hereby requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m., Eastern Time, on November 7, 2023, or as soon thereafter as possible.

Please direct any questions or comments concerning this request to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671. Also, please notify Mr. Abrams when this request for acceleration has been granted.

PORTAGE BIOTECH INC.

By: /s/ Allan Shaw

Name: Allan Shaw

Title: Chief Financial Officer

Show Raw Text

CORRESP
1
filename1.htm

PORTAGE BIOTECH INC.

Clarence Thomas Building, P.O. Box 4649

Road Town, Tortola

British Virgin Islands, VG1110

November 3, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Dillon Hagius

    Re:
    Portage Biotech Inc.

    Registration Statement on Form F-1

    Filed October 31, 2023

    File No. 333-275229

    Request for Acceleration of Effective Date

Mr. Hagius:

Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended, Portage Biotech Inc. hereby requests that the U.S. Securities
and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement on Form F-1 (the “Registration
Statement”) and declare the Registration Statement effective as of 4:00 p.m., Eastern Time, on November 7, 2023, or as soon thereafter
as possible.

Please direct any questions
or comments concerning this request to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671. Also, please notify Mr. Abrams when this
request for acceleration has been granted.

    PORTAGE BIOTECH INC.

    By:
    /s/ Allan Shaw

    Name:
    Allan Shaw

    Title:
    Chief Financial Officer

SecProbe.io